Recombinant Human EphB6 Protein

Cat. No.: rp145625

GRADE & PURITY Animal Free, Carrier Free, Bioactive, ActiBioPure™, His Tag, ≥90%(SDS-PAGE)

Accession #

NP_004436.1

Protein Tag

C-10His

Expression system

HEK293

Endotoxin Concentration

<0.1 EU/μg

Bioactivity

Measured by its binding ability in a functional ELISA. Immobilized rhEphB6/at 2 µg/mL (100 µL/well) can bind rmEphrin-B2/Fc Chimera with a linear range of 0.0780-5.00 ng/mL.

Overview

Kinase-defective receptor for members of the ephrin-B family. Binds to ephrin-B1 and ephrin-B2. Modulates cell adhesion and migration by exerting both positive and negative effects upon stimulation with ephrin-B2. Inhibits JNK activation, T cell receptor-induced IL-2 secretion and CD25 expression upon stimulation with ephrin-B2.

Post-translational:

Ligand-binding increases phosphorylation on tyrosine residues. Phosphorylation on tyrosine residues is mediated by transphosphorylation by the catalytically active EPHB1 in a ligand-independent manner. Tyrosine phosphorylation of the receptor may act as a switch on the functional transition from cell adhesion/attraction to de-adhesion/repulsion.

Specifications

Product Name

Recombinant Human EphB6 Protein

Synonyms

EC 2.7.10.1 | EPH receptor B6 | EphB6 | ephrin type-B receptor 6 | Hep | Tyrosine-protein kinase-defective receptor EPH-6 | Mep | MGC129910 | MGC129911

Grade

ActiBioPure™, Animal Free, Bioactive, Carrier Free, His Tag

Specifications & Purity

Animal Free, Carrier Free, Bioactive, ActiBioPure™, His Tag, ≥90%(SDS-PAGE)

Bioactivity

Measured by its binding ability in a functional ELISA. Immobilized rhEphB6/at 2 µg/mL (100 µL/well) can bind rmEphrin-B2/Fc Chimera with a linear range of 0.0780-5.00 ng/mL.

Endotoxin Concentration

<0.1 EU/μg

Species

Human

Amino Acids

17-579 aa

Sequence

LEEVLLDTTGETSEIGWLTYPPGGWDEVSVLDDQRRLTRTFEACHVAGAPPGTGQDNWLQTHFVERRGAQRAHIRLHFSVRACSSLGVSGGTCRETFTLYYRQAEEPDSPDSVSSWHLKRWTKVDTIAADESFPSSSSSSSSSSSAAWAVGPHGAGQRAGLQLNVKERSFGPLTQRGFYVAFQDTGACLALVAVRLFSYTCPAVLRSFASFPETQASGAGGASLVAAVGTCVAHAEPEEDGVGGQAGGSPPRLHCNGEGKWMVAVGGCRCQPGYQPARGDKACQACPRGLYKSSAGNAPCSPCPARSHAPNPAAPVCPCLEGFYRASSDPPEAPCTGPPSAPQELWFEVQGSALMLHWRLPRELGGRGDLLFNVVCKECEGRQEPASGGGGTCHRCRDEVHFDPRQRGLTESRVLVGGLRAHVPYILEVQAVNGVSELSPDPPQAAAINVSTSHEVPSAVPVVHQVSRASNSITVSWPQPDQTNGNILDYQLRYYDQAEDESHSFTLTSETNTATVTQLSPGHIYGFQVRARTAAGHGPYGGKVYFQTLPQGELSSQLPERLSHHHHHHHHHH

Accession #

NP_004436.1

Predicted molecular weight

61.5 kDa

SDS-PAGE

60-70 kDa, under reducing conditions

Molecule Type

Protein

Storage and Shipping

Shape

Lyophilized

Reconstitution

Reconstitute in sterile water to a concentration of 0.1-0.5 mg/ml.

Storage

Store at -20°C,Avoid repeated freezing and thawing

Shipped In

Ice chest + Ice pads

Stability And Storage

Store at -20~-80℃ for more than 1 year. Upon delivery aliquot. Avoid freeze/thaw cycle.

Images

SDS-PAGE: Recombinant Human EphB6 Protein (rp145625)

Recombinant Human EphB6 Protein (rp145625) - SDS-PAGE 

2 μg/lane of Recombinant Human EphB6 Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing the band at 69 kDa under reducing condition and 65 kDa under non-reducing condition.

Application Protocols

• Item-specific (Product Data)

  • Tested applications, recommended dilutions, and positive controls: Not specified for this item; refer to CoA/Spec Sheet.

• General protocols (literature/good practice)

  • Direct ELISA using recombinant EphB6
    • Coat: Dilute to 1–5 µg/mL in carbonate buffer (pH 9.6) or PBS; incubate overnight at 4 °C.
    • Block: 1–5% BSA or casein in PBS, 1 h at room temp.
    • Incubate: Add ephrin-B-Fc or detection antibody serial dilutions (0.05–50 nM) in PBS + 0.05% Tween-20 + 0.1% BSA; 1 h at room temp.
    • Wash: 3–5× with PBS-T.
    • Detect: HRP-conjugate and TMB; stop with acid and read at 450 nm.
  • SPR via His-tag capture (NTA chip)
    • Activate NTA, inject 0.5 mM NiCl2; capture His-tagged EphB6 to 50–300 RU in HBS-N or HBS-EP (pH 7.4).
    • Inject analyte (ephrin-B ectodomain) in 2-fold series across expected KD; 25 °C; reference-subtract; fit with 1:1 or heterogenous ligand model as appropriate.
    • Regenerate with 350 mM EDTA if needed; recharge with Ni2+.
  • Pull-down with Ni-NTA resin
    • Equilibrate resin in 20 mM HEPES, 150 mM NaCl, 10–20 mM imidazole, pH 7.4.
    • Bind His-tagged EphB6 (on ice); add interaction partner; incubate 30–120 min at 4 °C.
    • Wash with buffer containing 20–40 mM imidazole; elute with 250–300 mM imidazole.
  • BLI setup
    • Load His-tagged EphB6 on NTA sensors; equilibrate in assay buffer with 0.01% Tween-20 and 0.1% BSA; perform association/dissociation at 25 °C.

• Notes

  • For carrier-free protein, pre-block plasticware or include inert carrier to minimize adsorption at low nM/pM levels.
  • Validate linear range and signal-to-noise for each platform before quantitation.

Biological Roles

• Literature/general biology of EphB6 (not item-specific claims)

  • Family and function: EphB6 is a member of the Eph receptor family, which mediates cell–cell communication through interactions with membrane-bound ephrin-B ligands. Unlike catalytically active EphB receptors, EphB6 is kinase-impaired and signals via adaptor-mediated complexes, influencing cytoskeletal organization, adhesion, and migration.
  • Bidirectional signaling: Eph–ephrin engagement triggers forward signaling in Eph-expressing cells and reverse signaling in ephrin-expressing cells. EphB6 can modulate signaling thresholds and network topology by forming complexes with other Eph receptors and scaffold proteins.
  • Expression context: Reported in epithelial and immune lineages (literature), where it may modulate contact-dependent processes and responsiveness to environmental cues.
  • Molecular interactions: Binds ephrin-B ligands in the extracellular space; intracellularly associates with adaptors such as GRB2 and CBL (literature), enabling downstream effects despite reduced catalytic activity.
  • Structural features relevant to function: The ectodomain confers ligand-binding specificity; the cytoplasmic region contains a kinase-like domain, SAM domain, and PDZ-binding motifs that organize protein networks.

• Research utility of recombinant EphB6 (general)

  • Serves as a defined, controllable reagent to dissect Eph–ephrin binding thermodynamics and to reconstitute clustering-dependent signaling in vitro. Soluble ectodomains can act as binding partners or competitors to parse specificity and affinity determinants in the Eph/ephrin system.

Buffer Applications

• Item-specific (Product Data)

  • Supplied buffer and recommended reconstitution medium: Not specified for this item; refer to CoA/Spec Sheet.

• Literature/general buffer guidance for recombinant EphB6 assays

  • Storage buffers: Neutral pH (7.2–7.6) PBS or HEPES with 100–300 mM NaCl help maintain solubility. For long-term frozen aliquots, 5–10% glycerol or 0.5 M trehalose can enhance stability (validate for your assay).
  • Working buffers for binding assays: PBS or HBS (10 mM HEPES, 150 mM NaCl) with 0.005–0.05% Tween-20 reduces nonspecific adsorption in ELISA, SPR, and BLI. Maintain temperature control to minimize drift.
  • Low-adsorption handling: For carrier-free protein, include inert blockers (e.g., 0.1% casein or 1% BSA) in the assay buffer or plate-blocking step if compatible with detection.
  • Chelators: Avoid EDTA/EGTA if relying on His-tag immobilization (Ni-NTA). If metal chelators are necessary (e.g., to suppress metal-mediated artifacts), immobilize via alternative chemistry (e.g., amine coupling).
  • Filtration/sterility: Filter buffers through 0.22 µm membranes to reduce particulates for optical methods. Degas for SPR to suppress bubble formation.
  • pH stability checks: Verify protein integrity across the intended pH range using quick screens (DSF, CD) before committing to large-scale experiments, as local conformational changes can impact binding readouts.

Green Alternatives

• Context: Protein reagents do not typically involve hazardous organic solvents in use; sustainability focuses on buffer choices, waste minimization, and cold-chain efficiency.

• Greener practice options (general)

  • Buffer systems: Prefer phosphate or HEPES buffers prepared from high-purity salts and ultrapure water; avoid volatile amines or buffers requiring hazardous pH adjustments. Prepare concentrates to reduce packaging and shipping weight.
  • Stabilization to reduce waste: Aliquot on receipt to avoid freeze–thaw losses; consider adding benign stabilizers (e.g., trehalose or glycerol at validated levels) to extend working life, decreasing repeated orders and shipments.
  • Assay platforms: Use label-free methods (SPR/BLI/MST) that minimize fluorescent dye waste. If fluorescent labeling is required, select aqueous-compatible, high-QY dyes and quench unreacted dye efficiently to reduce organic solvent use.
  • Cold-chain efficiency: Coordinate deliveries to consolidate shipments. Utilize energy-efficient −20 °C storage when compatible with the product and workflow (item-specific storage is −20 °C).
  • Consumables: Choose low-binding, recyclable plastics where validated. Rinse and reuse Ni-NTA resins when compatible with quality requirements to reduce single-use materials.

• Comparison snapshot (general)

  • Traditional approach: Multiple small-volume shipments, frequent freeze–thaw cycles, and single-use plastics can increase footprint.
  • Greener approach: Bulk purchase with planned aliquoting, validated long-term stabilizers, and recyclable consumables reduces material and energy use without compromising data quality.

Pharmaceutical Uses

• Applicability note: This research-grade material is not for clinical use. The following describe formulation/manufacturing research contexts without therapeutic claims.

• Literature/general roles in pharmaceutical R&D workflows

  • Assay development: Recombinant EphB6 can serve as a reference reagent for high-throughput screening (HTS) of modulators of Eph–ephrin interactions, and for orthogonal confirmation by SPR/BLI.
  • Analytical controls: Use as a positive control in immunoassays (e.g., anti-EphB6 ELISAs) or as a system-suitability standard in SEC-MALS or CE-SDS method development targeting receptor ectodomains.
  • Binding reagents in mechanism studies: Define structure–activity relationships for biologics (e.g., Fc-fusions, antibodies, or alternative scaffolds) that target EphB6 or that use EphB6 as a specificity counter-screen.
  • Formulation research: Evaluate excipient effects on receptor ectodomain stability (salts, sugars, polyols) to inform platform formulations for similar proteins.

• Compliance and documentation

  • Pharmacopoeial status: No monograph is implied for this item. Any pharmacopeia conformity, endotoxin specifications, or residual host contaminant limits are Not specified for this item; refer to CoA/Spec Sheet.
  • Traceability: For regulated environments, retain lot-specific documentation (CoA, SDS) and maintain chain-of-custody for samples incorporated into method validation or characterization studies.

Physical Properties

• Item-specific (Product Data)

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Buffer composition, concentration, and excipients: Not specified for this item; refer to CoA/Spec Sheet.

• Literature/general values and considerations (not item specifications)

  • Full-length human EphB6 precursor length is ~1,059 amino acids (UniProt Q9UF33); calculated unglycosylated mass for full-length protein is typically >110 kDa (literature). Ectodomain-only recombinant constructs (commonly used for binding assays) are often ~55–80 kDa without glycosylation, but actual values depend on the construct and tag.
  • Isoelectric point (pI): Sequence-dependent; extracellular domains of Eph receptors often exhibit pI in the acidic-to-neutral range; exact pI must be computed from the specific construct sequence.
  • Solubility: Recombinant EphB6 proteins are typically supplied in aqueous buffered saline (e.g., PBS or HEPES) and are soluble at application-relevant concentrations (ng/mL–mg/mL) when properly folded; aggregation propensity can increase at low ionic strength or near the pI (general protein behavior).
  • Stability: Stabilized by neutral pH (≈7.2–7.5), moderate ionic strength (100–300 mM NaCl), and inclusion of carrier protein or sugars/polyols as needed; avoid repeated freeze–thaw cycles to minimize aggregation (general guidance).
  • Optical properties: Protein UV absorbance at 280 nm follows the Beer–Lambert law based on Tyr/Trp/Cys content; the exact extinction coefficient depends on the construct sequence (can be computed from the provided sequence on request).

Quality and Grades

• Item-specific (Product Data)

  • Grade/Purity: Animal Free, Carrier Free, Bioactive, ActiBioPure™, His Tag.

• What these designations mean (general definitions and implications)

  • Animal Free: Manufactured without animal-derived raw materials, reducing risk of adventitious agents and enabling consistent performance in defined systems. Suitable for applications sensitive to animal components (e.g., receptor–ligand biophysics, cell-defined media development), but verify exact process on the CoA if regulatory alignment is needed.
  • Carrier Free: Supplied without protein carriers (e.g., BSA). Advantages: precise mass balance and unconfounded readouts in binding/enzymology. Consider adding your own carrier (e.g., 0.1% HSA/BSA or 5–10% glycerol) after reconstitution to reduce adsorption if ultralow concentrations will be used.
  • Bioactive: Functionally validated in one or more biological assay formats (e.g., ligand binding or cell-based response) by the manufacturer. Note: Exact assay(s) and acceptance criteria are not specified here; refer to the CoA/Spec Sheet for the verification method.
  • ActiBioPure™: Proprietary quality branding indicating high purity and activity retention. Specific metrics (SDS-PAGE purity %, endotoxin level, host cell protein/DNA, residuals) are Not specified for this item; refer to CoA/Spec Sheet.
  • His Tag: Polyhistidine affinity tag facilitates Ni2+/Co2+-chelate purification and downstream capture (e.g., pull-down, SPR chip loading). Position (N- vs C-terminal), linker, and exact tag length are Not specified for this item; refer to CoA/Spec Sheet.

• Practical QC notes

  • For quantitative work, request lot-specific data: purity by SDS-PAGE/SEC, endotoxin (EU/µg), identity (MS/peptide mapping), concentration (A280), and bioactivity assay description.

Reaction and Applications

• Applicability note: As a recombinant receptor protein, this product is used in biochemical/biophysical assays rather than chemical synthesis reactions.

• Typical research applications (literature/general)

  • Ligand-binding and interaction studies: Quantify binding to ephrin-B family ligands (e.g., EFNB1/2/3 ectodomains or Fc-fusions) using ELISA, SPR, BLI, or MST. Because EphB6 is catalytically impaired, signaling is assessed via clustering-dependent adaptor recruitment rather than autophosphorylation readouts.
  • Receptor clustering assays: Plate-bound EphB6 or ephrin-B can induce receptor/ligand clustering on cells expressing counterparts, enabling studies of adhesion and contact-mediated signaling.
  • Pull-down/affinity capture: His-tag enables immobilization on Ni-NTA/IDA resin or chelator-functionalized biosensor surfaces to characterize protein–protein interactions (e.g., with GRB2, c-CBL; literature) or to screen modulators.
  • Cell-based assays: As a substrate/ligand partner in co-culture or conditioned-media contexts to probe Eph-ephrin bidirectional signaling (forward in Eph-expressing cells; reverse in ephrin-expressing cells). Verify presentation state (soluble vs clustered) for physiological relevance.
  • Analytical standards: Calibration controls for immunoassays detecting EphB6 or for method development in SEC-MALS and SDS-PAGE.

• Practical tips

  • Use carrier-free material to avoid matrix interference in sensitive biophysical methods; add your own minimal stabilizer post-dilution if nonspecific loss is observed.
  • Cluster ephrin or receptor ectodomains using secondary antibodies or streptavidin-biotin systems where appropriate to mimic membrane tethering.
  • Validate construct compatibility (extracellular domain vs full-length) with your assay hypothesis.

Reaction Conditions

• Applicability note: No chemical reactions are performed with this protein. The following summarizes general assay conditions for protein–protein interaction measurements (literature/general guidance; not item specifications).

• Typical conditions for binding/biophysical assays

  • ELISA/plate binding: Coat 1–5 µg/mL ligand or receptor in carbonate buffer (pH 9.6) or directly in PBS overnight at 4 °C; block with 1–5% BSA/casein; detect bound partner over 0.05–50 nM range, depending on affinity; wash with PBS + 0.05% Tween-20.
  • SPR (e.g., CM5, NTA chips): Running buffer HBS-N or HBS-EP (10 mM HEPES, 150 mM NaCl, ±0.005% surfactant, pH 7.4). For His-tag capture on NTA: load at 50–300 RU; inject analyte across 0.1–100 nM; 25 °C; regenerate with 350 mM EDTA (if not required for subsequent cycles) or low-pH glycine if amine-coupled.
  • BLI: NTA or AR2G sensors; equilibrate in assay buffer with 0.01% Tween-20 and 0.1% BSA; typical analyte series 0.5–100 nM; 25 °C.
  • Pull-down: Bind His-tagged protein to Ni-NTA resin (10–40 mM imidazole in binding buffer to reduce nonspecifics, 150–300 mM NaCl, pH 7.4); incubate prey 30–120 min at 4 °C; wash and elute with 250–300 mM imidazole.
  • Cell clustering assays: Present ephrin-B or EphB6 on surfaces or beads to induce clustering; maintain physiological buffers at 37 °C; assess downstream markers via immunoblot or imaging.

• Notes

  • Verify construct (extracellular domain vs full-length) and tag position, as these determine immobilization strategies and orientation.
  • Optimize detergent and salt to balance low nonspecific binding with preserved activity. Always include negative controls (e.g., unrelated His-tagged protein).

Safety and Handling

• Item-specific (Product Data)

  • GHS Classification, Signal Word, H-Statements, Pictograms: Not specified for this item; refer to SDS.
  • Storage Conditions: Store at −20 °C. Avoid repeated freezing and thawing.
  • Shipping: Shipped in an ice chest with ice pads (cold chain).
  • Research Use Note: For research use only.

• General safety guidance (defer to SDS for authoritative instructions)

  • Expected hazard profile: Recombinant proteins in neutral buffers are generally considered low hazard; however, treat as laboratory chemicals. Avoid inhalation, ingestion, and contact with skin/eyes.
  • PPE: Laboratory coat, gloves (nitrile), and safety glasses. Handle in a clean area to prevent microbial contamination and protein degradation.
  • Hygienic practices: Work on ice for prolonged handling. Use sterile, nuclease-free plasticware and buffers to prevent proteolysis or contamination. Dispose of waste according to institutional biosafety procedures.
  • Incompatibilities: Avoid strong oxidizers, extreme pH (<5 or >9), and organic solvents that denature proteins. Avoid metal-chelating agents (e.g., EDTA) if downstream use depends on His-tag/Ni-affinity interactions.
  • First-aid overview: In case of skin/eye contact, rinse with water for at least 15 minutes; if inhaled, move to fresh air; if ingested, rinse mouth and seek medical attention. Consult the SDS for detailed response measures.
  • Special risks: Freeze–thaw-induced aggregation and activity loss. Use aliquots to minimize activity decline and adsorption losses with carrier-free material.

Solvent Selection

• Applicability note: This is a recombinant protein; solvent considerations focus on aqueous buffer systems rather than organic solvents.

• Item-specific (Product Data)

  • Supplied buffer and excipients: Not specified for this item; refer to CoA/Spec Sheet.

• Literature/general buffer selection guidance for Eph-family recombinant proteins

  • Base buffers: Phosphate-buffered saline (PBS, 10–20 mM phosphate, 150 mM NaCl, pH 7.2–7.5) or HEPES (10–25 mM, 150 mM NaCl, pH 7.2–7.6) provide isotonic, near-physiological conditions that maintain ectodomain integrity.
  • Ionic strength: 100–300 mM NaCl typically reduces non-specific interactions and aggregation in binding assays (ELISA, SPR, BLI).
  • Additives: For carrier-free material, consider 0.05–0.1% nonionic detergent (Tween-20) in assay buffers to limit surface adsorption (do not add detergents to long-term storage unless validated). For long-term frozen aliquots, 5–10% glycerol can improve freeze–thaw resilience. Avoid chelators if using His-tag affinity.
  • Divalent cations: Eph–ephrin binding does not strictly require Ca2+/Mg2+, but including 1–2 mM MgCl2 can stabilize some protein–protein interactions; verify for your assay.
  • pH: Maintain near-neutral pH (7.2–7.6). Deviations can alter charge distribution and binding.
  • Organic solvents: Avoid; even low percentages of DMSO/MeOH can perturb tertiary structure. If small-molecule modulators require DMSO, keep final DMSO ≤1–2% and include matching controls.

Storage and Reconstitution

• Item-specific (Product Data)

  • Storage Conditions: Store at −20 °C. Avoid repeated freezing and thawing.
  • Shipped In: Ice chest + ice pads (maintain cold chain).
  • Appearance, supplied concentration, and buffer composition: Not specified for this item; refer to CoA/Spec Sheet.

• General reconstitution guidance for recombinant, carrier-free His-tag proteins (not item specifications)

  • Reconstitution medium: Use sterile, neutral buffer (e.g., PBS or 10–20 mM HEPES, 150 mM NaCl, pH 7.2–7.5). For ultralow adsorption, include 0.1% carrier protein (HSA/BSA) if compatible with downstream assays. If long-term freezing is planned, 5–10% glycerol may be added after initial characterization.
  • Procedure: Allow vial to equilibrate to room temperature inside a desiccated environment to prevent condensation. Briefly centrifuge to collect contents. Add buffer in small volume, gently flick or pipette—avoid vigorous vortexing. Incubate on ice for 5–10 min to fully hydrate. If necessary, clarify by brief low-speed spin.
  • Aliquoting: Prepare single-use aliquots in low-bind tubes to minimize freeze–thaw cycles. Label with lot, concentration, and date.
  • Short-term storage: 2–8 °C for hours to a few days if stability has been verified.
  • Long-term storage: −20 °C per item-specific guidance; −80 °C may further preserve activity if compatible with formulation (validate). Avoid frost-free freezers.
  • Thawing: Thaw on ice; mix gently. Do not refreeze the same aliquot. Keep samples cold during setup.
  • Stability monitoring: Periodically assess integrity by SDS-PAGE and, if applicable, SEC for aggregation and a functional binding assay to confirm activity retention.

Structure and Identity

• Item-specific (Product Data)

  • Name: Recombinant Human EphB6 Protein (His-tag)
  • SKU: rp145625
  • CAS: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES / InChI / InChIKey: Not applicable to proteins; not specified for this item.
  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

• Literature/general identity (for the human protein target)

  • Gene/protein: EphB6 (EPHB6), a member of the Eph receptor tyrosine kinase family (EphB subclass). EphB6 is catalytically impaired (pseudokinase-like) but participates in signaling via adaptor proteins.
  • Canonical sequence reference: UniProt Q9UF33 (literature), length ~1,059 aa for full-length human EphB6 precursor.
  • Domain architecture (typical for EphB receptors, literature): N-terminal signal peptide; extracellular region containing one Ig-like domain followed by two fibronectin type III (FN3) domains; single-pass transmembrane helix; intracellular region with a juxtamembrane segment and a kinase-like domain that is catalytically inactive in EphB6; C-terminal SAM and PDZ-binding motifs.
  • Post-translational features (literature): Multiple N-glycosylation sites in the ectodomain; potential phosphorylation sites in the cytoplasmic tail when co-signaling.

• 2D structural description in words (literature)

  • A modular, single-pass type I transmembrane receptor with a globular N-terminal ligand-binding module that recognizes ephrin-B ligands, two rod-like FN3 domains, a membrane-spanning helix, and a cytosolic tail harboring a kinase-like fold and docking motifs. Recombinant formats may include isolated extracellular domains or tagged constructs; exact construct details for this item are not specified.

Synthetic Utility

• Applicability note: This section typically covers small-molecule building blocks. As a recombinant protein, EphB6 is not a synthetic intermediate and is not used in organic transformations.

• Relevant utility in a biochemical sense (literature/general)

  • Affinity handle: The His tag enables selective capture/immobilization on IMAC matrices for pull-downs, co-immunoprecipitation alternatives, and oriented presentation on biosensor chips.
  • Modular assembly: Recombinant ectodomains can be combined with multimerization scaffolds (e.g., Fc, streptavidin-biotin, nanoparticles) to study clustering-dependent signaling phenomena in a controlled manner.
  • Assay construction: Serves as a defined component in reconstituted signaling systems and in specificity panels to differentiate EphB-class binding profiles.

• If your focus is chemical synthesis: Consider browsing small-molecule Eph–ephrin modulators or fragment libraries; this protein product itself does not substitute for a chemical reagent in synthesis.

Target Specificity

• Applicability note: Target specificity, clone, isotype, and species reactivity are attributes of antibody products. This item is a recombinant human protein, not an antibody.

• Item-specific (Product Data)

  • No antibody-specific data (antigen/epitope/clone) are provided for this protein product.

• Literature/general information

  • EphB6 recognizes ephrin-B ligands via its extracellular ligand-binding domain (protein–protein interaction specificity). Any binding constants, epitope mappings, or cross-reactivity patterns are assay- and construct-dependent and are Not specified for this item; refer to primary literature for your chosen assay format.